loading
Schlusskurs vom Vortag:
$72.28
Offen:
$72.65
24-Stunden-Volumen:
333.92K
Relative Volume:
0.95
Marktkapitalisierung:
$1.66B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
18.34
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-2.17%
1M Leistung:
-1.77%
6M Leistung:
-7.40%
1J Leistung:
-21.38%
1-Tages-Spanne:
Value
$71.50
$73.08
1-Wochen-Bereich:
Value
$69.90
$74.28
52-Wochen-Spanne:
Value
$69.58
$97.00

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name
Firmenname
Ani Pharmaceuticals Inc
Name
Telefon
(609) 759-1810
Name
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Name
Mitarbeiter
970
Name
Twitter
Name
Nächster Verdiensttermin
2026-11-06
Name
Neueste SEC-Einreichungen
Name
ANIP's Discussions on Twitter

Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ANIP icon
ANIP
Ani Pharmaceuticals Inc
72.29 1.66B 923.71M 84.68M 182.81M 3.9419
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.67 62.84B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.13 44.55B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
79.38 32.80B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
533.12 22.87B 3.17B 1.29B 1.01B 27.09

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-09-23 Eingeleitet Oppenheimer Perform
2026-09-09 Eingeleitet Leerink Partners Outperform
2026-07-17 Eingeleitet Canaccord Genuity Hold
2025-07-10 Eingeleitet H.C. Wainwright Buy
2025-03-14 Eingeleitet Jefferies Buy
2025-03-12 Eingeleitet JP Morgan Overweight
2024-12-11 Eingeleitet Leerink Partners Outperform
2024-10-11 Eingeleitet Piper Sandler Overweight
2024-03-15 Eingeleitet CapitalOne Overweight
2023-08-22 Bestätigt H.C. Wainwright Buy
2023-03-01 Eingeleitet Guggenheim Buy
2022-09-07 Eingeleitet H.C. Wainwright Buy
2021-11-02 Eingeleitet Truist Buy
2020-05-07 Herabstufung Cantor Fitzgerald Overweight → Neutral
2019-09-12 Eingeleitet Guggenheim Buy
2019-05-10 Herabstufung Raymond James Strong Buy → Outperform
2017-10-16 Bestätigt Canaccord Genuity Buy
2017-07-31 Eingeleitet Canaccord Genuity Buy
2017-02-22 Herabstufung ROTH Capital Buy → Neutral
2016-06-23 Eingeleitet Raymond James Strong Buy
2016-05-24 Herabstufung Standpoint Research Buy → Hold
2015-11-13 Eingeleitet Standpoint Research Buy
2015-09-28 Hochstufung ROTH Capital Neutral → Buy
2015-08-05 Bestätigt Oppenheimer Outperform
2015-08-04 Bestätigt ROTH Capital Neutral
2015-07-31 Bestätigt Oppenheimer Outperform
2015-07-15 Bestätigt ROTH Capital Neutral
2015-06-23 Bestätigt Oppenheimer Outperform
2015-05-18 Bestätigt ROTH Capital Neutral
2015-05-06 Bestätigt Oppenheimer Outperform
2015-04-10 Herabstufung ROTH Capital Buy → Neutral
2015-02-26 Bestätigt ROTH Capital Buy
2015-02-18 Bestätigt Oppenheimer Outperform
Alle ansehen

Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten

pulisher
Oct 13, 2026

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 06, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 01, 2026

ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

Form 4 ANI Pharmaceuticals Inc For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026
pulisher
Oct 01, 2026

Ani Pharmaceuticals SVP & CFO Stephen Carey sells $208,050 in stock - Investing.com

Oct 01, 2026
pulisher
Sep 30, 2026

ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada

Sep 30, 2026
pulisher
Sep 30, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares - MarketBeat

Sep 30, 2026
pulisher
Sep 30, 2026

After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. - Stock Titan

Sep 30, 2026
pulisher
Apr 03, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Sep 30, 2026

ANI Pharmaceuticals Announces New Fluocinolone Acetonide - GlobeNewswire

Sep 30, 2026
pulisher
Sep 30, 2026

Data on an eye implant for chronic eye inflammation will be presented in a late-breaking talk Oct. 9. - Stock Titan

Sep 30, 2026
pulisher
Sep 29, 2026

ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 29, 2026
pulisher
Sep 28, 2026

Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo Finance UK

Sep 28, 2026
pulisher
Sep 28, 2026

Implied Volatility Surging for ANI Pharmaceuticals Stock Options - TradingView

Sep 28, 2026
pulisher
Sep 28, 2026

Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo! Finance Canada

Sep 28, 2026
pulisher
Sep 26, 2026

183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE - MarketBeat

Sep 26, 2026
pulisher
Sep 24, 2026

ANIP5868601 Bond Profile: Coupon and Redemption - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP) - Seeking Alpha

Sep 24, 2026
pulisher
Sep 24, 2026

ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance Singapore

Sep 24, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals gets FDA approval for generic everolimus - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals Receives FDA Approval for Generic Everolimus Tablets for Oral Suspension - Quiver Quantitative

Sep 23, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire

Sep 23, 2026
pulisher
Sep 23, 2026

Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions - simplywall.st

Sep 23, 2026
pulisher
Sep 21, 2026

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth - Eastern Progress

Sep 21, 2026
pulisher
Sep 16, 2026

ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares in pre-set trading plan - Stock Titan

Sep 16, 2026
pulisher
Sep 15, 2026

ANI Pharmaceuticals (NASDAQ: ANIP) insider lines up $380,000 stock sale for 2026 - Stock Titan

Sep 15, 2026
pulisher
Sep 14, 2026

ANI Pharmaceuticals (ANIP) insider sells 500 shares - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock - Investing.com

Sep 14, 2026
pulisher
Sep 14, 2026

ANI Pharmaceuticals (ANIP) director sells 1,000 shares in planned trade - Stock Titan

Sep 14, 2026
pulisher
Sep 13, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Sep 13, 2026
pulisher
Sep 13, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 13, 2026
pulisher
Sep 11, 2026

ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan

Sep 11, 2026
pulisher
Sep 11, 2026

WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Sep 11, 2026
pulisher
Sep 10, 2026

ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace - Investing.com Canada

Sep 10, 2026
pulisher
Sep 09, 2026

ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com South Africa

Sep 09, 2026
pulisher
Sep 09, 2026

ETFs Investing in ANI Pharmaceuticals, Inc. Stocks - tradingview.com

Sep 09, 2026
pulisher
Sep 09, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week LowTime to Sell? - MarketBeat

Sep 09, 2026
pulisher
Sep 09, 2026

ANI Pharmaceuticals stock hits 52-week low at 70.03 USD - investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat

Sep 09, 2026
pulisher
Sep 05, 2026

Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Sep 05, 2026
pulisher
Sep 04, 2026

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board - Yahoo Finance

Sep 04, 2026
pulisher
Sep 03, 2026

ANI Pharmaceuticals to Present at September Investor Conferences - The Manila Times

Sep 03, 2026
pulisher
Sep 03, 2026

ANI Pharmaceuticals to Present at September Investor Conferences - Yahoo Finance

Sep 03, 2026

Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ani Pharmaceuticals Inc-Aktie (ANIP) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Oct 13 '26
Sale
73.59
500
36,795
73,424
CAREY STEPHEN P.
SVP & CFO
Sep 29 '26
Sale
73.00
2,850
208,050
168,993
Lalwani Nikhil
PRESIDENT & CEO
Sep 15 '26
Sale
71.00
5,400
383,400
339,089
NIKHIL LALWANI
Director
Sep 15 '26
Proposed Sale
70.40
5,400
380,160
0
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Sep 14 '26
Sale
70.79
500
35,395
73,924
JEANNE THOMA
Director
Sep 11 '26
Proposed Sale
71.46
1,000
71,460
0
Thoma Jeanne
Director
Sep 11 '26
Sale
71.53
1,000
71,530
26,762
CAREY STEPHEN P.
SVP & CFO
Aug 31 '26
Sale
72.80
2,850
207,480
171,843
Lalwani Nikhil
PRESIDENT & CEO
Aug 25 '26
Sale
74.30
5,400
401,220
344,489
NIKHIL LALWANI
Director
Aug 25 '26
Proposed Sale
74.17
5,400
400,518
0
$38.82
price up icon 2.21%
$5.00
price down icon 5.84%
$36.34
price up icon 0.03%
$10.31
price up icon 2.38%
$50.31
price down icon 1.99%
$10.01
price down icon 2.82%
Kapitalisierung:     |  Volumen (24h):